Scholarlink

<p>The progression of colorectal cancer (CRC) is highly dependent on tumor angiogenesis, a process primarily regulated by hypoxia-inducible factor HIF-1α. This study focuses on the mechanistic role of protein arginine methyltransferase 6 (PRMT6) in CRC angiogenesis and reveals that PRMT6 is significantly overexpressed in CRC tissues, stabilizing HIF-1α via the autophagy-lysosome pathway. Specifically, PRMT6 catalyzes the asymmetric dimethylation of HIF-1α at arginine 463, which disrupts its interaction with the autophagy-related protein TAX1BP1, thereby preventing its degradation. In vivo experiments demonstrate that PRMT6 silencing reduces HIF-1α stability, decreases vascular endothelial growth factor A (VEGFA) expression, and markedly suppresses tumor angiogenesis and growth. This study identifies the PRMT6-HIF-1α axis as a novel therapeutic target for CRC and suggests that targeting this pathway may facilitate the development of precision anti-angiogenic therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PRMT6 acts as a pro-angiogenic factor in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月11日

查看全文
  • Haifeng Han,
  • Xin Zhang,
  • Mingxin Jin,
  • Yali Chu,
  • Fengjun Liu,
  • Hui Qu,
  • Cheng Chen

摘要

The progression of colorectal cancer (CRC) is highly dependent on tumor angiogenesis, a process primarily regulated by hypoxia-inducible factor HIF-1α. This study focuses on the mechanistic role of protein arginine methyltransferase 6 (PRMT6) in CRC angiogenesis and reveals that PRMT6 is significantly overexpressed in CRC tissues, stabilizing HIF-1α via the autophagy-lysosome pathway. Specifically, PRMT6 catalyzes the asymmetric dimethylation of HIF-1α at arginine 463, which disrupts its interaction with the autophagy-related protein TAX1BP1, thereby preventing its degradation. In vivo experiments demonstrate that PRMT6 silencing reduces HIF-1α stability, decreases vascular endothelial growth factor A (VEGFA) expression, and markedly suppresses tumor angiogenesis and growth. This study identifies the PRMT6-HIF-1α axis as a novel therapeutic target for CRC and suggests that targeting this pathway may facilitate the development of precision anti-angiogenic therapies.